Clinical Trial Update: Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents [Phase 3]

View source ↗

Summary

Phase III trial in breast cancer comparing gemcitabine plus a cytotoxic agent to two cytotoxic agents has completed; sponsor is Eli Lilly.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED